# Endo Dpp4i Correction Insulin Vs Scheduled Insulin Select T2d

> Recommends either a dipeptidyl peptidase-4 inhibitor with correction insulin or scheduled insulin therapy for select adult patients with mild hyperglycemia and type 2 diabetes hospitalized for noncritical illness. Consider when HbA1c <7.5%, blood glucose <180 mg/dL, and total daily insulin dose <0.6 units/kg if previously on insulin.

- Skill: `dromlakhani/endo-dpp4i-correction-insulin-vs-scheduled-insulin-select-t2` (Agent Skill)
- Install (CLI): `npx skillmds@latest add dromlakhani/endo-dpp4i-correction-insulin-vs-scheduled-insulin-select-t2`
- Raw SKILL.md: https://api.skillmd.com/api/skills/dromlakhani/endo-dpp4i-correction-insulin-vs-scheduled-insulin-select-t2/raw
- Safety review: pending (external: skill-scanner PASS, skillspector PASS)
- Works with: Claude Code, Claude.ai, OpenAI Codex
- Category: Coding & Dev Tools
- Author: dromlakhani (https://skillmd.com/u/dromlakhani)
- Updated: 2026-09-08
- Page: https://skillmd.com/skills/dromlakhani/endo-dpp4i-correction-insulin-vs-scheduled-insulin-select-t2

---


# Consider DPP4 inhibitor with correction insulin or scheduled insulin for select mild hyperglycemia type 2 diabetes patients

## STEP 1 — Gather Information
Collect HbA1c (within past 3 months), current blood glucose, diabetes type, prior insulin use and total daily dose, hospitalization context (noncritical illness), and assess for contraindications (T1D, renal impairment, pancreatitis). If HbA1c <7.5%, BG <180 mg/dL, and (if insulin-naïve or TDD <0.6 units/kg) proceed; otherwise, consider alternative regimens.

## STEP 2 — Rule In / Rule Out
Rule in if: HbA1c <7.5% (9.4 mmol/L), BG <180 mg/dL (10 mmol/L), and (if previously on insulin) total daily dose <0.6 units/kg/day; rule out if any criterion fails or if T1D/other insulin-dependent diabetes is present.

## STEP 3 — Classify or Stratify
Stratify by patient preference and safety: prefer DPP4i + correction insulin for oral therapy desire and low hypoglycemia risk; choose scheduled insulin if DPP4i contraindicated (eGFR <30, history of pancreatitis), patient prefers insulin, or cost/access issues.

## STEP 4 — Decide
Initiate selected regimen: DPP4i (e.g., sitagliptin 100 mg daily) with correction insulin (rapid-acting analogue per sliding scale) OR scheduled insulin (basal ± nutritional insulin) targeting glucose 100–180 mg/dL.

## Clinical Guardrails / Mimics / Pitfalls
Do not use in type 1 diabetes, persistent hyperglycemia >180 mg/dL on DPP4i, eGFR <30 without dose adjustment, history of pancreatitis, or if patient cannot afford medication; avoid sliding scale insulin alone without scheduled basal in hyperglycemic patients.

## Concrete Clinical Example
A 68‑year‑old woman with T2D (HbA1c 7.2%, BG 150 mg/dL, no prior insulin) admitted for community‑acquired pneumonia (noncritical) meets criteria; she prefers oral therapy, so start sitagliptin 100 mg daily plus insulin aspart correction scale (2 units if BG 150–180, 4 units if 181–250).

**Source:** Management of Hyperglycemia in Hospitalized Adult Patients in Non-Critical Care Settings: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2022, https://doi.org/10.1210/clinem/dgac278

> **TODO:** consider adding scripts/calc.py for the endo-dpp4i-correction-insulin-vs-scheduled-insulin-select-t2d calculator